Dosing Begins in Trial of Rheumatoid Arthritis Treatment

I-Mab, a biopharmaceutical firm, has begun dosing participants in Phase Ib of their trial of plonmarlimab, a rheumatoid arthritis (RA) treatment. Developers of the medication believe that it could become a viable, disease-modifying treatment option for those with RA.

About Rheumatoid Arthritis (RA)

Rheumatoid arthritis is a chronic, inflammatory disorder that affects many joints throughout the body. Symptoms are progressive in most cases, and many go through periods of remission and active symptoms. Effects include pain in the joints, muscles, and back, swelling, stiffness, weakness, tenderness, fatigue, anemia, lumps or redness in the skin, bumps on the fingers, a pins and needles sensation, dry mouth, and physical deformity. In severe cases, affected individuals can see a restriction in movements because their joints are so stiff. There are many treatment options for this condition, ranging from inflammation and pain medication to transcutaneous electrical nerve stimulation.

Plonmarlimab for RA

Plonmarlimab is a humanized immunoglobulin G1 antibody that acts upon a stimulating factor that has been associated with a number of inflammatory diseases. It is then meant to suppress the inflammatory responses that are seen in rheumatoid arthritis. Medical professionals hope that this treatment will address an unmet need and offer a viable treatment for those with RA.

In terms of the trial, it will be double-blind, placebo-controlled, and conducted through multiple centers. 63 participants with RA have been enrolled in the effort to test the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of  plonmarlimab. If all goes well, there could be another treatment option for those with rheumatoid arthritis in the not too distant future.

Find the source article here.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email